Anoctamin 5 promotes colon cancer progression and predicts poor prognosis
/S checkpoint progression. Immunohistochemistry of tumors from 200 patients with stage II/III CC demonstrated high ANO5 expression in 52% of cases. High expression was significantly associated with poorer outcomes, with 5-year relapse-free survival (62.6% vs. 87.3%, p < 0.001) and overall survival (74.0% vs. 94.8%, p < 0.001) markedly worse in the high-expression group. Multivariate analyses confirmed high ANO5 expression as an independent prognostic factor. Collectively, ANO5 promotes tumor cell growth, survival, and motility, and its high expression predicts unfavorable clinical outcomes, indicating its potential as a prognostic biomarker and therapeutic target in CC.
Authors
- Jun Kiuchi (ORCID: https://orcid.org/0000-0002-0787-1955)
- Michihiro Kudou
- Shuhei Komatsu (ORCID: https://orcid.org/0000-0001-6074-7614)
- Atsushi Shiozaki (ORCID: https://orcid.org/0000-0003-3739-160X)
- Hirotaka Konishi (ORCID: https://orcid.org/0000-0002-4899-8944)
- Toshiyuki Kosuga (ORCID: https://orcid.org/0000-0002-1657-7272)
- Kenji Nanishi (ORCID: https://orcid.org/0000-0002-3169-360X)
- Tomohiro Arita (ORCID: https://orcid.org/0000-0001-7127-6504)
- Hiroki Shimizu
- Kento Kurashima
- Takayuki Miyoshi
- Hiroyuki Inoue
- Yukiko Morinaga
- Motohiro Kojima
Institutions
- Kyoto Prefectural University of Medicine (JP)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-05-12
- DOI
- https://doi.org/10.1038/s41598-026-47958-w
- Primary Topic
- Cell Adhesion Molecules Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00